Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients

Ablynx ’s partner Merck has presented new data from a Phase Ib trial of the bi-specific anti-IL-17A/F Nanobody (M1095; ALX-0761) in patients with psoriasis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news